Embryo TransferPhase 3NCT07499817
Effect of Pentoxyfilline on Endometrial Thickness and Frozen Embryo Transfer Outcomes
A Phase 3 study testing pentoxifylline 400 mg in people with Embryo Transfer and IVF, run by Beni-Suef University at 1 site in Egypt.
Trial summary
The aim of this work was to investigate the effect of different vasodilators as pentoxifylline in women with unexplained infertility using IVF Read more about this study
- Who is it for?
- Ages 18 to 43 years, women only
- Conditions the study is for
- Embryo Transfer, IVF, Infertility
- What is being tested?
- pentoxifylline 400 mg
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 100 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Oct 2023to 30 Apr 2026
- Phase
- Phase 3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 43 years
- Women only
- No healthy volunteers
- Adult
Who may be able to join
- as good quality day five frozen embryos.
Who cannot join
- history of endocrine diseases,
- history of any previous surgery that couldm compromise the integrity of endometrium,
- cardiovascular, renal and liver diseases,
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Egypt1 site, 1 recruiting
- Recruiting
Beni-suef university Hospital
Banī Suwayf, Beni Suweif Governorate, 62521
Beni Suef University, 082 2356845 ext. 2, info@bsu.edu.eg
About this study
The aim of this work was to investigate the effect of different vasodilators as pentoxifylline in women with unexplained infertility using IVF
Read the detailed description
A prospective randomized clinical study was carried out on 100 women, aged <18 to 43 years old, has good quality day five frozen embryos. The study was done after approval from the Ethical Committee Beni Suef University Hospitals, Beni Suef, Egypt. An informed written consent was obtained from the patients.
Randomization and blindness:
An online randomization program (http://www.randomizer.org ) was used to generate a random list and each patient's code was kept in an opaque sealed envelope. Patients were randomly allocated with 1:1 allocation ratio into two equal groups in a parallel manner: Group 1 (control):
received estradiol valerate 2 mg. in form of (Cycloprogynova® Bayer Shering Pharma) whitepills starting dose is one pill T.I.D may be increased to two pills T.I.D according to endometrial5 thickness in day 9 measured by vaginal ultrasound.
Group 2: received pentoxifylline 400 mg. Once daily in form of (Trental ® Sanofi co.) daily in addition to the above treatment protocol from the first day of the cycle until the day of starting progesterone.
All patients were subjected to complete history taking, general examination, laboratory investigations [Anti-müllerian hormone (AMH), follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E₂), prolactin (PRL) and thyroid-stimulating hormone (TSH)] and radiological investigations [Ultrasonography]. The endometrial thickness was estimated by transvaginal ultrasonography.
- Conditions
- Embryo Transfer, IVF, Infertility
- Being tested
- pentoxifylline 400 mg, (control)
- Keywords
- thawed embryo, IVF
- Medical subject headings
- Infertility
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
pentoxifylline 400 mgDrug
Also called Trental ® Sanofi co.
Once daily in form of (Trental ® Sanofi co.) daily in addition to the above treatment protocol from the first day of the cycle until the day of starting progesterone.
(control)Other
estradiol valerate 2 mg. in form of (Cycloprogynova® Bayer Shering Pharma) whitepills starting dose is one pill T.I.D
| Study group | Role | What they receive |
|---|---|---|
| (control) | Active comparator | received estradiol valerate 2 mg. in form of (Cycloprogynova® Bayer Shering Pharma) white pills starting dose is one pill T.I.D may be increased to two pills T.I.D according to endometrial5 thickness in day 9 measured by vaginal ultrasound Receives: Other: (control) |
| pentoxifylline 400 mg | Experimental | Once daily in form of (Trental ® Sanofi co.) daily in addition to the above treatment protocol from the first day of the cycle until the day of starting progesterone. Receives: Drug: pentoxifylline 400 mg |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pregnancy
Beta-Human Chorionic Gonadotropin (β-hCG) was positive
Measured: 1 month
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Mar 2026
- Study start1 Oct 2023
- Primary completion1 Apr 2026 (estimated)
- Study completion30 Apr 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Embryo TransferStudies of the same condition, open and under way.
- More trials run by Beni-Suef UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Beni-Suef University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Sara Abdallah Mohamed Salem, Beni-Suef University
- Investigators
- Beni suef University, Principal investigator, Beni-Suef University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07499817
- Sponsor's protocol ID
- Trental /IVF
- Status last verified
- Mar 2026
- First submitted
- 19 Mar 2026
- Last updated
- 30 Mar 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 30 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Pentoxyfilline on Endometrial Thickness and Frozen Embryo Transfer Outcomes
- ClinicalTrials.gov ID
- NCT07499817
- Acronym / sponsor ID
- Trental /IVF
- Conditions
- Embryo Transfer, IVF, Infertility
- Keywords
- thawed embryo, IVF
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Beni-Suef UniversityUniversity, hospital or other
- Study start
- 1 Oct 2023 (actual)
- Primary completion
- 1 Apr 2026 (estimated)
- Study completion
- 30 Apr 2026 (estimated)
- First posted
- 30 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this work was to investigate the effect of different vasodilators as pentoxifylline in women with unexplained infertility using IVF
Detailed description
A prospective randomized clinical study was carried out on 100 women, aged <18 to 43 years old, has good quality day five frozen embryos. The study was done after approval from the Ethical Committee Beni Suef University Hospitals, Beni Suef, Egypt. An informed written consent was obtained from the patients.
Randomization and blindness:
An online randomization program (http://www.randomizer.org ) was used to generate a random list and each patient's code was kept in an opaque sealed envelope. Patients were randomly allocated with 1:1 allocation ratio into two equal groups in a parallel manner: Group 1 (control):
received estradiol valerate 2 mg. in form of (Cycloprogynova® Bayer Shering Pharma) whitepills starting dose is one pill T.I.D may be increased to two pills T.I.D according to endometrial5 thickness in day 9 measured by vaginal ultrasound.
Group 2: received pentoxifylline 400 mg. Once daily in form of (Trental ® Sanofi co.) daily in addition to the above treatment protocol from the first day of the cycle until the day of starting progesterone.
All patients were subjected to complete history taking, general examination, laboratory investigations [Anti-müllerian hormone (AMH), follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E₂), prolactin (PRL) and thyroid-stimulating hormone (TSH)] and radiological investigations [Ultrasonography]. The endometrial thickness was estimated by transvaginal ultrasonography.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| (control) | Active comparator | Other: (control)received estradiol valerate 2 mg. in form of (Cycloprogynova® Bayer Shering Pharma) white pills starting dose is one pill T.I.D may be increased to two pills T.I.D according to endometrial5 thickness in day 9 measured by vaginal ultrasound |
| pentoxifylline 400 mg | Experimental | Drug: pentoxifylline 400 mgOnce daily in form of (Trental ® Sanofi co.) daily in addition to the above treatment protocol from the first day of the cycle until the day of starting progesterone. |
Who may qualify
- Ages
- 18 to 43 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (1 listed)
- as good quality day five frozen embryos.
Key exclusion criteria (3 listed)
- history of endocrine diseases,
- history of any previous surgery that couldm compromise the integrity of endometrium,
- cardiovascular, renal and liver diseases,
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| pentoxifylline 400 mgAlso: Trental ® Sanofi co.Once daily in form of (Trental ® Sanofi co.) daily in addition to the above treatment protocol from the first day of the cycle until the day of starting progesterone. | Drug | pentoxifylline 400 mg |
| (control)estradiol valerate 2 mg. in form of (Cycloprogynova® Bayer Shering Pharma) whitepills starting dose is one pill T.I.D | Other | (control) |
Primary outcome
Pregnancy
Time frame: 1 month
Beta-Human Chorionic Gonadotropin (β-hCG) was positive
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Mar 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Embryo Transfer
Not yet recruiting
Cryopreserved Pre-embryo Transfer in a Cytokine-rich Medium Versus Hyaluronic Acid
Frozen Embryo Transfer (FET)
Active, not recruitingPhase 3
Human Menopausal Gonadotropin Research in Infertility Assessing Cumulative Live Birth With Frozen Embryo Transfer.
Infertility (IVF Patients)
Not yet recruitingObservational study
Linzagolix in Adenomyosis and Recurrent Implantation Failure
Adenomyosis of Uterus, Implantation Failure
RecruitingPhase 2
Effect of FB301 on Vaginal Bacterial Profile in Women With Asymptomatic Vaginal Dysbiosis Undergoing a Mock Frozen Embryo Transfer Cycle
Vaginal Dysbiosis
RecruitingPhase 2/3
Thymosin-α1 for Recurrent Implantation Failure
Recurrent Implantation Faliure
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Beni suef University principal investigator
Beni-Suef University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing pentoxifylline 400 mg in people with Embryo Transfer and IVF, run by Beni-Suef University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 30 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Sara A Salem, MD (01272842226 ext. 02, sara.abdalla@med.bsu.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pregnancy (time frame: 1 month). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Mar 2026.